Metastatic Melanoma Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

Description

The metastatic melanoma cancer diagnostics market is on the brink of substantial growth, driven by advancements in diagnostic technologies and heightened awareness of skin cancer. Projections indicate the market will reach $3.6992 billion in 2024 and expand to $6.422 billion by 2031, showcasing a strong compound annual growth rate (CAGR) of 8.2%. This growth is bolstered by the increasing use of sophisticated diagnostic tools such as PET scans, MRI, and CT scans, which enhance diagnostic accuracy and efficiency.

Emerging Market Opportunities in India and China

Emerging economies, notably India and China, are emphasizing cost-effective diagnostic and therapeutic solutions, presenting significant opportunities for market players. The rising investments in healthcare infrastructure and government-led research and development initiatives in these regions are anticipated to drive the demand for metastatic melanoma diagnostics. Despite these advancements, early diagnosis rates for metastatic melanoma remain low in developing countries. The Indian Journal of Cancer highlights a significant gap in early detection and high mortality rates associated with skin cancer in these regions. The Asia-Pacific region, including Australia, continues to experience high incidences of skin cancer, underscoring the need for improved diagnostic measures.

Market Analysis and Trends

The global metastatic melanoma cancer diagnostics market has experienced steady growth in recent years, a trend that is expected to continue. This growth is driven by the increasing adoption of advanced imaging technologies. Magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) are gaining popularity due to their ability to provide precise diagnostic information. These technologies offer improved cancer staging, prognosis tracking, and treatment response monitoring, which are critical for effective patient management.

The shift towards minimally invasive or non-invasive diagnostic techniques is notable. These methods, which include non-invasive imaging and surgical diagnostics, offer benefits such as reduced recovery times, lower infection risks, and minimal physical intervention. The growing preference for these techniques among the elderly population and healthcare providers is driving the demand for advanced diagnostic instruments. As a result, companies are focusing on developing sophisticated products to meet this increasing demand.

Growth Drivers

Several key factors are driving the growth of the metastatic melanoma cancer diagnostics market. The rising prevalence of skin cancer and technological advancements are primary drivers. The development of effective cancer screening tools has significantly contributed to early detection efforts, thereby reducing mortality rates. Increased awareness and cancer screening initiatives over the past few decades have led to earlier diagnoses, although challenges remain in achieving comprehensive early detection.

Innovative diagnostic procedures that address the limitations of current screening methods, such as false positives and negatives, are gaining traction. These advanced diagnostic tools are expected to be rapidly adopted by healthcare professionals and patients alike, further driving market growth.

In regions such as Europe and the United States, where cancer incidence is higher, the focus on early detection and effective treatment has led to significant improvements in patient outcomes. The development of more effective systemic treatment regimens over the years has enhanced the diagnosis and treatment rates for melanoma, despite socioeconomic challenges and competing health priorities.

Market Challenges

However, several challenges hinder the market's growth. The high cost of medical imaging equipment is a significant barrier. Advanced diagnostic tools such as PET-CT and CT scans are expensive, and the necessary infrastructure to support these technologies adds to the overall cost. In developing countries, the financial burden associated with these diagnostic services can be prohibitive, limiting access to essential healthcare.

The substantial capital expenses involved in setting up diagnostic services, including equipment and operational costs, pose a significant challenge for low- and middle-income countries, where healthcare funding is limited. Additionally, the shortage of skilled personnel to operate these diagnostic facilities further impedes market expansion.

National healthcare authorities face the challenge of providing high-quality cancer care at an affordable price. The cost constraints and limited funding for operational expenses in many countries restrict the establishment of molecular diagnostic facilities, limiting the growth of the metastatic melanoma cancer diagnostics market.

Regional Insights

United States: The U.S. market is characterized by robust research and development activities and the presence of established medical device manufacturers. Early detection initiatives and the availability of skilled technicians have contributed to the region's market growth. The significant presence of biotechnology firms and adequate funding for research further bolster the market.
Germany: The rising incidence of malignant melanoma, driven by increased life expectancy and changing leisure activities, has positioned Germany as a lucrative market. Healthcare reforms and the reallocation of healthcare expenditures within the country are expected to support market growth.
China: China is emerging as a prominent market due to its large patient pool. The high incidence and mortality rates of cancer in the region highlight the need for effective diagnostic solutions. The increasing cancer cases are driving the demand for metastatic melanoma diagnostics in China.

Segment Insights

PET Scan: PET scans play a crucial role in detecting advanced stages of metastatic melanoma cancer. This imaging technique is particularly effective in identifying deep soft-tissue metastases, lymph node metastases, and visceral metastases. The high accuracy and efficiency of PET scans make them a dominant segment in the global market.
Pathology Laboratories: Pathology laboratories hold a significant share of the market, leveraging advanced digital technologies for cancer screening and detection. The integration of computational technologies enhances the safety, accuracy, and productivity of diagnostic processes. These advancements enable pathology laboratories to provide valuable insights into disease progression and facilitate appropriate treatment selection.

Competitive Analysis

The metastatic melanoma cancer diagnostics market is characterized by strategic collaborations among diagnostic product manufacturers, hospitals, and research institutes. These collaborations aim to enhance the efficacy of diagnostic tests and post-diagnosis treatments, thereby expanding market reach.

Leading players in the market include:

Amgen Inc.
Abbott Laboratories
Bristol-Myers Squibb
Novartis AG
F-Hoffmann-La Roche Ltd
Biomerieux
Quest Diagnostics
Agilent Technologies Inc.
Myriad Genetics Inc.
Qiagen

Key Segments Covered in Metastatic Melanoma Cancer Diagnostics Industry Research

Test:
- Biopsy

§ Local excision/excisional biopsy

§ Punch biopsy

§ Shave biopsy

§ Fine needle aspiration (FNA) biopsy

§ Sentinel lymph node biopsy

Chest X-ray
Ultrasound
CT Scan
MRI
PET SCAN

Service Provider:
- Hospitals
- Pathology Laboratories
- Cancer Research Centres
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa

1. Executive Summary

1.1. Global Metastatic Melanoma Cancer Diagnostics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Metastatic Melanoma Cancer Diagnostics Market Outlook, 2019 - 2031

3.1. Global Metastatic Melanoma Cancer Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Biopsy
    - 3.1.1.1.1. Local excision/excisional biopsy
    - 3.1.1.1.2. Punch biopsy
    - 3.1.1.1.3. Shave biopsy
    - 3.1.1.1.4. Fine needle aspiration (FNA) biopsy
    - 3.1.1.1.5. Sentinel lymph node biopsy
  - 3.1.1.2. Chest X-ray
  - 3.1.1.3. Ultrasound
  - 3.1.1.4. CT Scan
  - 3.1.1.5. MRI
  - 3.1.1.6. PET SCAN
3.2. Global Metastatic Melanoma Cancer Diagnostics Market Outlook, by Service Provider, Value (US$ Bn), 2019 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Hospitals
  - 3.2.1.2. Pathology Laboratories
  - 3.2.1.3. Cancer Research Centres
3.3. Global Metastatic Melanoma Cancer Diagnostics Market Outlook, by Region, Value (US$ Bn), 2019 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Metastatic Melanoma Cancer Diagnostics Market Outlook, 2019 - 2031

4.1. North America Metastatic Melanoma Cancer Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Biopsy
    - 4.1.1.1.1. Local excision/excisional biopsy
    - 4.1.1.1.2. Punch biopsy
    - 4.1.1.1.3. Shave biopsy
    - 4.1.1.1.4. Fine needle aspiration (FNA) biopsy
    - 4.1.1.1.5. Sentinel lymph node biopsy
  - 4.1.1.2. Chest X-ray
  - 4.1.1.3. Ultrasound
  - 4.1.1.4. CT Scan
  - 4.1.1.5. MRI
  - 4.1.1.6. PET SCAN
4.2. North America Metastatic Melanoma Cancer Diagnostics Market Outlook, by Service Provider, Value (US$ Bn), 2019 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Hospitals
  - 4.2.1.2. Pathology Laboratories
  - 4.2.1.3. Cancer Research Centres
- 4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Metastatic Melanoma Cancer Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 4.3.1.2. U.S. Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 4.3.1.3. Canada Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 4.3.1.4. Canada Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Metastatic Melanoma Cancer Diagnostics Market Outlook, 2019 - 2031

5.1. Europe Metastatic Melanoma Cancer Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Biopsy
    - 5.1.1.1.1. Local excision/excisional biopsy
    - 5.1.1.1.2. Punch biopsy
    - 5.1.1.1.3. Shave biopsy
    - 5.1.1.1.4. Fine needle aspiration (FNA) biopsy
    - 5.1.1.1.5. Sentinel lymph node biopsy
  - 5.1.1.2. Chest X-ray
  - 5.1.1.3. Ultrasound
  - 5.1.1.4. CT Scan
  - 5.1.1.5. MRI
  - 5.1.1.6. PET SCAN
5.2. Europe Metastatic Melanoma Cancer Diagnostics Market Outlook, by Service Provider, Value (US$ Bn), 2019 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Hospitals
  - 5.2.1.2. Pathology Laboratories
  - 5.2.1.3. Cancer Research Centres
- 5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Metastatic Melanoma Cancer Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 5.3.1.2. Germany Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 5.3.1.3. U.K. Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 5.3.1.4. U.K. Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 5.3.1.5. France Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 5.3.1.6. France Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 5.3.1.7. Italy Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 5.3.1.8. Italy Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 5.3.1.9. Turkey Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 5.3.1.10. Turkey Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 5.3.1.11. Russia Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 5.3.1.12. Russia Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 5.3.1.13. Rest of Europe Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 5.3.1.14. Rest of Europe Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Metastatic Melanoma Cancer Diagnostics Market Outlook, 2019 - 2031

6.1. Asia Pacific Metastatic Melanoma Cancer Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Biopsy
    - 6.1.1.1.1. Local excision/excisional biopsy
    - 6.1.1.1.2. Punch biopsy
    - 6.1.1.1.3. Shave biopsy
    - 6.1.1.1.4. Fine needle aspiration (FNA) biopsy
    - 6.1.1.1.5. Sentinel lymph node biopsy
  - 6.1.1.2. Chest X-ray
  - 6.1.1.3. Ultrasound
  - 6.1.1.4. CT Scan
  - 6.1.1.5. MRI
  - 6.1.1.6. PET SCAN
6.2. Asia Pacific Metastatic Melanoma Cancer Diagnostics Market Outlook, by Service Provider, Value (US$ Bn), 2019 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Hospitals
  - 6.2.1.2. Pathology Laboratories
  - 6.2.1.3. Cancer Research Centres
- 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Metastatic Melanoma Cancer Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 6.3.1.2. China Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 6.3.1.3. Japan Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 6.3.1.4. Japan Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 6.3.1.5. South Korea Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 6.3.1.6. South Korea Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 6.3.1.7. India Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 6.3.1.8. India Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 6.3.1.9. Southeast Asia Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 6.3.1.10. Southeast Asia Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 6.3.1.11. Rest of Asia Pacific Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 6.3.1.12. Rest of Asia Pacific Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Metastatic Melanoma Cancer Diagnostics Market Outlook, 2019 - 2031

7.1. Latin America Metastatic Melanoma Cancer Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Biopsy
    - 7.1.1.1.1. Local excision/excisional biopsy
    - 7.1.1.1.2. Punch biopsy
    - 7.1.1.1.3. Shave biopsy
    - 7.1.1.1.4. Fine needle aspiration (FNA) biopsy
    - 7.1.1.1.5. Sentinel lymph node biopsy
  - 7.1.1.2. Chest X-ray
  - 7.1.1.3. Ultrasound
  - 7.1.1.4. CT Scan
  - 7.1.1.5. MRI
  - 7.1.1.6. PET SCAN
7.2. Latin America Metastatic Melanoma Cancer Diagnostics Market Outlook, by Service Provider, Value (US$ Bn), 2019 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Hospitals
  - 7.2.1.2. Pathology Laboratories
  - 7.2.1.3. Cancer Research Centres
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Metastatic Melanoma Cancer Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 7.3.1.2. Brazil Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 7.3.1.3. Mexico Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 7.3.1.4. Mexico Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 7.3.1.5. Argentina Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 7.3.1.6. Argentina Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 7.3.1.7. Rest of Latin America Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 7.3.1.8. Rest of Latin America Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Metastatic Melanoma Cancer Diagnostics Market Outlook, 2019 - 2031

8.1. Middle East & Africa Metastatic Melanoma Cancer Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Biopsy
    - 8.1.1.1.1. Local excision/excisional biopsy
    - 8.1.1.1.2. Punch biopsy
    - 8.1.1.1.3. Shave biopsy
    - 8.1.1.1.4. Fine needle aspiration (FNA) biopsy
    - 8.1.1.1.5. Sentinel lymph node biopsy
  - 8.1.1.2. Chest X-ray
  - 8.1.1.3. Ultrasound
  - 8.1.1.4. CT Scan
  - 8.1.1.5. MRI
  - 8.1.1.6. PET SCAN
8.2. Middle East & Africa Metastatic Melanoma Cancer Diagnostics Market Outlook, by Service Provider, Value (US$ Bn), 2019 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Hospitals
  - 8.2.1.2. Pathology Laboratories
  - 8.2.1.3. Cancer Research Centres
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Metastatic Melanoma Cancer Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 8.3.1.2. GCC Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 8.3.1.3. South Africa Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 8.3.1.4. South Africa Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 8.3.1.5. Egypt Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 8.3.1.6. Egypt Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 8.3.1.7. Nigeria Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 8.3.1.8. Nigeria Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
  - 8.3.1.9. Rest of Middle East & Africa Metastatic Melanoma Cancer Diagnostics Market by Test, Value (US$ Bn), 2019 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Metastatic Melanoma Cancer Diagnostics Market by Service Provider, Value (US$ Bn), 2019 - 2031
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Test vs by Service Provider Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Amgen Inc
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Abbott Laboratories
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Bristol-Myers Squibb
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Novartis AG
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. F-Hoffmann-La Roche Ltd
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Biomerieux
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Quest diagnostics
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Agilent Technologies Inc
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Myriad Genetics Inc
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Qiagen
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations